---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Product comparison"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Product comparison. Topics: Diazoxide: the only FDA-approved drug labeled for hypoglycemia from inoperable islet cell tumors or extrapancreatic malignancy, Ersodetug compared with current medical therapies: manufacturer statements on site of action and limitations of comparators, Everolimus: labeled indication in pancreatic neuroendocrine tumors and hyperglycemia incidence, Tumor-directed agents with neuroendocrine tumor indications: lutetium Lu 177 dotatate and cabozantinib, and 2 further topics. 6 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/product-comparison"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Diazoxide: the only FDA-approved drug labeled for hypoglycemia from inoperable islet cell tumors or extrapancreatic malignancy

> “PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions:”
> “Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy.”
> “PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists.”

Source: [Proglycem prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/017453s025lbl.pdf)

<a id="topic-2.1.2.14-2"></a>

### Ersodetug compared with current medical therapies: manufacturer statements on site of action and limitations of comparators

> “Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion, and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of HI, including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia.”
> “Ersodetug for the treatment of HI is investigational.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

> “Diazoxide (DZ) is the only approved treatment but has suboptimal response rates and serious side effects”
> “Somatostatin analogs (SSAs) are used off-label with limited success, and may cause paradoxical worsening of hypoglycemia”
> “mTOR-inhibitors are used off-label and have potentially serious side effects”
> “DZ and SSAs do not work in NICTs because HI is not mediated by insulin”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

> “Currently available medical therapies are directed at reducing or eliminating insulin production and/or secretion from tumors, which may be challenging when the tumor is differentiated or dysregulated, and therefore not responding to usual control mechanisms for suppressing insulin production.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.1.2.14-3"></a>

### Everolimus: labeled indication in pancreatic neuroendocrine tumors and hyperglycemia incidence

> “AFINITOR is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.”
> “Hyperglycemia, hypercholesterolemia, and hypertriglyceridemia have been reported in patients taking AFINITOR/AFINITOR DISPERZ at an incidence up to 75%, 86%, and 73%, respectively.”

Source: [Afinitor prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022334s055lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

### Tumor-directed agents with neuroendocrine tumor indications: lutetium Lu 177 dotatate and cabozantinib

> “LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.”

Source: [Lutathera prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208700Orig1s032lbl.pdf)

> “CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).”

Source: [Cabometyx prescribing information (2025)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208692s019lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

### Hypoglycemia control across systemic therapies in malignant insulinoma: Mayo Clinic cohort

> “This study retrospectively analyzed 57 patients treated for malignant insulinoma at Mayo Clinic sites between 1992 and 2024, focusing on the efficacy of systemic therapies in improving hypoglycemic control and survival outcomes.”
> “PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).”
> “SSA, chemotherapy, and streptozocin were less effective, with hypoglycemic improvement seen in 37.5, 33.3, and 28.6% of patients, respectively.”

Source: [Koch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439997/)

<a id="topic-2.1.2.14-6"></a>

### Alpelisib: off-label use in insulin- or proinsulin-producing tumors

> “We present a case series describing the effectiveness and tolerability of the phosphatidylinositol 3-kinase inhibitor alpelisib in 2 women with metastatic insulin-producing or proinsulin-producing tumors.”
> “For the first patient, the proportion of glucose readings <54 mg/dL fell from 2.3% (95% CI, 2.1-2.4) to 0.2% (95% CI, 0.2%-0.3%), and the rate ratio was 0.087 (95% CI, 0.086-0.089).”
> “Due to high cost and off-label use, the process of obtaining alpelisib was complex and took several months for the first patient and 2 years for the second patient.”

Source: [Ryan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12268652/)

<a id="topic-2.1.2.14-7"></a>

### Direct comparisons of ersodetug with other therapies

No evidence found.

Additional sources: [Cahn et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37195951/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
